SBLENDORIO GLENN 4

What Happened

• Glenn Sblendorio, a director of Mineralys Therapeutics (MLYS), received two equity awards on 2026-02-19: 6,200 restricted stock units (RSUs) and 8,300 derivative awards (stock-option style). Both grants show an acquisition price of $0.00 on the Form 4 and were reported on 2026-02-20. These are grants/awards (not open-market buys or sales), so they are compensation-related rather than a market trade.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-20.
• Awards: 6,200 RSUs (A) at $0.00; 8,300 derivative award (A) at $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes:
  • F1: The 6,200 RSUs were granted for no additional cash; each RSU converts to one share upon vesting in one annual installment following the grant.
  • F2: The 8,300 derivative award is a stock option that vests in 12 substantially equal monthly installments after the grant date.
• Timeliness: Filing appears timely (period end 2026-02-19; filing 2026-02-20); no late filing flag noted.

Context

• RSUs convert into shares only upon vesting, and the option-style award vests monthly — neither represents immediately tradable shares at grant. Such grants are common director compensation to align interests with shareholders; they are informational but not direct bullish/bearish trades.